Key Points
- Amir Weiss sold 10,679 shares of Teva on May 6 at an average price of $36, totaling $384,444, leaving him with 20,016 shares (a 34.79% decrease in his holdings).
- Analysts remain largely positive with nine Buy ratings and one Sell, an average price target of $41.78, and notable raises including Goldman Sachs to $45 and Bank of America to $42.
- Teva reported quarterly EPS of $0.53 on $3.98 billion of revenue; the stock trades near $36 with a market cap of $41.39 billion, a P/E of 27.07, and a 52-week range of $14.99–$37.35.
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Get Free Report) CAO Amir Weiss sold 10,679 shares of the stock in a transaction that occurred on Wednesday, May 6th. The stock was sold at an average price of $36.00, for a total value of $384,444.00. Following the transaction, the chief accounting officer owned 20,016 shares in the company, valued at $720,576. The trade was a 34.79% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.
Teva Pharmaceutical Industries Price Performance
Teva Pharmaceutical Industries stock opened at $36.00 on Friday. The stock has a market capitalization of $41.39 billion, a price-to-earnings ratio of 27.07, a PEG ratio of 3.51 and a beta of 0.86. Teva Pharmaceutical Industries Ltd. has a 52-week low of $14.99 and a 52-week high of $37.35. The stock's 50 day moving average price is $31.28 and its two-hundred day moving average price is $29.81. The company has a debt-to-equity ratio of 1.70, a quick ratio of 0.78 and a current ratio of 1.01.
Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its quarterly earnings results on Tuesday, March 31st. The company reported $0.53 earnings per share (EPS) for the quarter. The firm had revenue of $3.98 billion for the quarter. Teva Pharmaceutical Industries had a return on equity of 43.53% and a net margin of 9.01%. On average, equities analysts predict that Teva Pharmaceutical Industries Ltd. will post 2.49 earnings per share for the current year.
Hedge Funds Weigh In On Teva Pharmaceutical Industries
A number of large investors have recently modified their holdings of the company. Harel Insurance Investments & Financial Services Ltd. lifted its holdings in shares of Teva Pharmaceutical Industries by 2.2% in the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 45,956,714 shares of the company's stock worth $1,384,216,000 after purchasing an additional 1,004,941 shares in the last quarter. Phoenix Financial Ltd. lifted its holdings in shares of Teva Pharmaceutical Industries by 9.4% in the 3rd quarter. Phoenix Financial Ltd. now owns 41,295,244 shares of the company's stock worth $834,164,000 after purchasing an additional 3,533,800 shares in the last quarter. WCM Investment Management LLC lifted its holdings in shares of Teva Pharmaceutical Industries by 191.4% in the 1st quarter. WCM Investment Management LLC now owns 40,820,600 shares of the company's stock worth $1,157,264,000 after purchasing an additional 26,813,522 shares in the last quarter. Menora Mivtachim Holdings LTD. lifted its holdings in shares of Teva Pharmaceutical Industries by 1.1% in the 3rd quarter. Menora Mivtachim Holdings LTD. now owns 38,920,294 shares of the company's stock worth $786,190,000 after purchasing an additional 427,000 shares in the last quarter. Finally, Clal Insurance Enterprises Holdings Ltd lifted its holdings in shares of Teva Pharmaceutical Industries by 18.8% in the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 37,404,106 shares of the company's stock worth $1,171,378,000 after purchasing an additional 5,917,423 shares in the last quarter. 54.05% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
A number of equities analysts have issued reports on TEVA shares. Wall Street Zen cut Teva Pharmaceutical Industries from a "strong-buy" rating to a "hold" rating in a report on Saturday, May 2nd. The Goldman Sachs Group increased their price target on Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the stock a "buy" rating in a report on Monday, February 9th. Bank of America increased their price target on Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the stock a "buy" rating in a report on Thursday, April 9th. JPMorgan Chase & Co. increased their price target on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock an "overweight" rating in a report on Thursday, April 30th. Finally, Scotiabank increased their price target on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock a "sector outperform" rating in a report on Thursday, January 29th. Nine analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $41.78.
Check Out Our Latest Analysis on TEVA
About Teva Pharmaceutical Industries
(
Get Free Report)
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world's largest manufacturers of generic medicines. The company's core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.
Teva's product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
